These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100 [TBL] [Abstract][Full Text] [Related]
4. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice. Ceballos-Baumann A; Häck HJ Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400 [TBL] [Abstract][Full Text] [Related]
5. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K; Lyons KE Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805 [TBL] [Abstract][Full Text] [Related]
6. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. Sanford M; Scott LJ CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211 [TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal patch for the treatment of Parkinson's Disease. Perez-Lloret S; Rey MV; Ratti PL; Rascol O Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451 [TBL] [Abstract][Full Text] [Related]
8. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Naidu Y; Chaudhuri KR Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409 [TBL] [Abstract][Full Text] [Related]
12. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH; Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234 [TBL] [Abstract][Full Text] [Related]
13. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome. Splinter MY Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296 [TBL] [Abstract][Full Text] [Related]
14. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. Zareba G Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608 [TBL] [Abstract][Full Text] [Related]
15. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951 [TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Rascol O; Perez-Lloret S Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399 [TBL] [Abstract][Full Text] [Related]
17. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. Baldwin CM; Keating GM CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483 [TBL] [Abstract][Full Text] [Related]
18. Drug safety evaluation of rotigotine. Sprenger FS; Seppi K; Poewe W Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676 [TBL] [Abstract][Full Text] [Related]
19. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Boroojerdi B; Wolff HM; Braun M; Scheller DK Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503 [TBL] [Abstract][Full Text] [Related]
20. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. Giladi N; Boroojerdi B; Surmann E J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]